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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.002Liposarcoma is a type of soft tissue sarcoma that exhibits poor survival and a high recurrence rate.
Treatment is generally limited to surgery and radiation, which emphasizes the need for better under-
standing of this disease. Because very few in vivo and in vitro models can reproducibly recapitulate the
human disease, we generated several xenograft models from surgically resected human dedifferentiated
liposarcoma. All xenografts recapitulated morphological and gene expression characteristics of the patient
tumors after continuous in vivo passages. Importantly, xenograftability was directly correlated with
disease-speciﬁc survival of liposarcoma patients. Thus, the ability for the tumor of a patient to engraft may
help identify those patients who will beneﬁt from more aggressive treatment regimens. Gene expression
analyses highlighted the association between xenograftability and a unique gene expression signature,
including down-regulated PTEN tumor-suppressor gene expression and a progenitor-like phenotype. When
treated with the PI3K/AKT/mTOR pathway inhibitor rapamycin alone or in combination with the multi-
kinase inhibitor sorafenib, all xenografts responded with increased lipid content and a more differentiated
gene expression proﬁle. These human xenograft models may facilitate liposarcoma research and accelerate
the generation of readily translatable preclinical data that could ultimately inﬂuence patient care.
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York, New York.Liposarcoma (LPS), a neoplasm arising within adipose tissue
that is thought to originate from mesenchymal stem cells,1e3
is a type of soft tissue sarcoma and is associated with poor
patient outcomes.4e6 LPS is classiﬁed into three histolog-
ical subtypes: well-differentiated/dedifferentiated (WD/DD),
pleomorphic, andmyxoid/round cell. Of these,WD/DD is the
most prevalent subtype. The extent of differentiation, as re-
ﬂected by histological grade, remains the most important
determinant of patient outcome. The main treatment options
for patients with LPS are surgery and radiation, because
chemotherapy typically has little effect on the overall prog-
nosis for patients with locally advanced or metastatic
disease.7,8
The establishment of a clinically relevant disease model is
vital in studying the molecular mechanisms underlying LPS
malignant transformation and evaluating emerging targetedstigative Pathology.
.therapies. Certain characteristic mutations of LPS have been
identiﬁed, such as chromosome 12q ampliﬁcation in WD/
DD LPS and a chromosomal translocation in myxoid LPS4;
however, our knowledge of the cell-of-origin and major
pathway alterations associated with LPS is still limited. In
the present study, we developed a direct LPS xenograft
method by implanting and serially passaging freshly resec-
ted LPS samples from patients into immunodeﬁcient mice.
PTEN and PI3K Pathway in LiposarcomaWe demonstrated that these xenograft models not only
recapitulate the patient tumors, but carry a unique gene
expression signature and can be used for testing targeted
treatment.
Materials and Methods
Collection of Tumor Samples
Patients with suspected LPS who underwent surgery at the
University of California, Los Angeles (UCLA), were
enrolled on an Institutional Review Boardeapproved tissue
procurement protocol after giving written informed consent.
Each surgically resected tumor was sliced into sections with
a sterile razor blade and was divided as follows: one portion
was immediately frozen and stored at 80C for genomic
and gene expression analyses, another portion of the tumor
was ﬁxed in 10% formalin for histology, and the remainder
was minced into small pieces for xenograft implantation and
tissue culture studies. Histological review by a sarcoma
pathologist (S.M.D.) conﬁrmed diagnosis, subtype, and
grade of tumors used in the present study.
Xenograft Implantation and Passage
Transplantation studies were performed using NOD.CB17-
Prkdcscid/J (common name, NOD-SCID) or NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (common name, NSG) immunodeﬁcient mice
acquired from colonies bred in-house at UCLA. For the initial
xenograft, approximately 100 mg of the patient tumor was cut
into fragments (approximately 3 mm3), using a sterile razor
blade.Micewere anesthetizedwith isoﬂurane, and the fur on the
hindquarters was shaved and prepared with an antiseptic agent.
An incision was made, and one of the tumor fragments
(approximately 3 mm3) was inserted into the subdermal space.
The incision was closed with either 5-0 Prolene suture or a skin
stapler; the closure was removed on postoperative day 10. Mice
weremaintained inbarrier cages on standard chowdietwith food
and water available ad libitum; 2 mg/mL sulfamethoxazole and
0.4mg/mL trimethoprimwas added to drinkingwater to prevent
infection. All studies were performed in accordance with the
UCLAAnimalResearchCommittee andDivision ofLaboratory
Animal Medicine (protocol no. 96-126). All surgery was per-
formed under isoﬂurane anesthesia, and all efforts were made to
minimize suffering.
Implanted samples were allowed a 6-month incubation
period to form a palpable tumor. When successful engraft-
ment occurred, tumors were collected before reaching 1.5
cm in diameter. Harvested tumors were separated into three
fragments: for histopathology, gene expression analysis, and
serial transplantation for establishing stable xenograft
models or cell culture models.
Tissue Dissociation for Xenografts
Single-cell suspensions from tumors were generated using
eithermechanical dissociation or cell straining. FormechanicalThe American Journal of Pathology - ajp.amjpathol.orgdissociation, the gentleMACS dissociator (Miltenyi Biotec,
Auburn, CA) was used. Approximately 2 mg of tumor was
added to a gentleMACSC tube containing 5mLof enzymatic
solution: 0.85 mg/mL Gibco collagenase (Life Tech-
nologieseInvitrogen, Carlsbad, CA) in Dulbecco’s modiﬁed
Eagle’s medium (DMEM), 10% fetal bovine serum, 1%
penicillin/streptomycin. The C tube was placed upside down
onto the sleeve of the dissociator, and gentleMACS programs
C and D were run in succession. The tube was removed from
the machine, and the material was applied to a 70-mm cell
strainer, without force, into a 50-mL tube. The cell strainer
was rinsed with 10 mL of Dulbecco’s phosphate buffered
saline (DPBS), and the resulting solution was centrifuged at
300 g for 10minutes, aspirated, and resuspended in DPBS.
Another dissociation method involved cutting the tumor into
2- to 4-mm pieces and, using the blunt end of a syringe
plunger, manually straining the pieces through a 100-mm cell
ﬁlter into 5 to 10 mL of DPBS. The cells were centrifuged at
300 g for 10minutes, aspirated, and resuspended in DPBS.
For cryopreservation, tissue was manually strained
through a 100-mm cell ﬁlter with the blunt end of a syringe
into 1 to 2 mL of freezing medium (10% dimethyl sulfoxide
and 90% fetal bovine serum). Cells were then gradually
frozen at 80C and cryopreserved for at least 24 hours
before being rapidly thawed in a 37C water bath. After
addition of 10 mL of DPBS, the cells were centrifuged, the
supernatant was discarded, and cells were resuspended in
DPBS. Cells were counted on a hemocytometer using
Trypan Blue exclusion and concentration was adjusted to
5  106 cells/mL. Mice were anesthetized with isoﬂurane,
fur on the hindquarters was shaved, and the skin was
prepared with an antiseptic agent. Approximately 0.5  106
to 1.0  106 cells were injected subcutaneously with a
28-gauge needle on a 0.5-mL insulin syringe.
Tissue Culture
Tumor tissue samples (200 to 300 mg) were minced with
a scalpel and then were dissociated by carefully passing
them in complete medium (basal medium supplemented
with 10% fetal bovine serum and 1% penicillin/strepto-
mycin) through a 40-mm cell strainer. Three basal media
were tested: DMEM, 1:1 DMEM/Ham’s F12 medium, and
RPMI-1640 medium. Cells were spun down at 150  g for
5 minutes, resuspended in 10 mL of red cell lysis buffer
(150 mmol/L ammonium chloride, 1 mmol/L potassium
bicarbonate, 0.1 mmol/L EDTA), and incubated at room
temperature for 10 minutes. After 5 minutes of spinning
down at 150  g, cells were resuspended in complete
medium and plated onto six-well dishes (106 cells per well).
Cell adhesion was observed 24 hours after plating, and
conﬂuent plates were expanded. Cells were maintained in
a 37C incubator with a 5% CO2eenriched atmosphere and
were monitored for cell adhesion.
For inoculation in mice, 70% conﬂuent cells were rinsed
with DPBS and treated with 0.25% trypsineEDTA (Life1401
Smith et alTechnologieseInvitrogen) until the cells separated from
the dish. Complete medium was added to quench the
trypsin reaction, and the cells were centrifuged at 150  g
for 5 minutes. The supernatant was aspirated and cells
were resuspended in DPBS, counted on a hemocytometer
using Trypan Blue exclusion, and adjusted to a concentra-
tion of 5  106 cells/mL. Mice were anesthetized with
isoﬂurane, fur in the injection region was shaved, the skin
was prepared with an antiseptic, and 0.5  106 to 1.0  106
cells were injected subcutaneously with a 28-gauge needle
on a 0.5-mL insulin syringe.
Histology and Immunohistochemistry
The sample was ﬁxed in 10% phosphate-buffered formalin
overnight and then was transferred into 50% to 70%
ethanol. Shortly afterward, the tissue was embedded in
parafﬁn using standard protocols, cut into sections (4 mm
thick), stained with H&E at the UCLA Translational
Pathology Core Laboratory, and reviewed by a sarcoma
pathologist (S.M.D). Slides were digitally scanned at 400
magniﬁcation using an Aperio XL system (Aperio, Vista,
CA), and images were analyzed using ImageScope version
11.1.2.752 (Aperio) and Adobe Photoshop CS4 version
11.0.2 software.
For immunohistochemical analysis, formalin-ﬁxed, parafﬁn-
embedded sections were deparafﬁnized in xylene and rehy-
drated in graded alcohol. Endogenous peroxidase activity
was blocked with 3% hydrogen peroxide. Antigen retrieval
was performed by boiling the sections in 0.01 mol/L citric
acid buffer (pH 6.0) for 15 minutes. Sections were ﬁrst
blocked with 5% normal donkey serum in DPBS, and then
incubated with primary antibody against Ki-67 (1:500;
Vector Laboratories, Burlingame, CA), PTEN (1:100), p-S6
(Ser240/244, 1:100), or p-ERK (Thr202/Tyr204, 1:300; all
from Cell Signaling Technology, Danvers, MA) overnight at
4C. Sections were then incubated with 1:500 biotinylated
secondary antibody (Jackson ImmunoResearch Laborato-
ries, West Grove, PA) for 1 hour at room temperature.
Antibody binding was detected with a Vectastain Elite ABC
kit (PK-6100; Vector Laboratories) and visualized with 3,30-
diaminobenzidine (DAB; Vector Laboratories). Sections
were counterstained in hematoxylin.
For visualizing lipids, frozen sections were stained in
a 0.3% Oil Red O/isopropyl alcohol solution for 7 to 10
minutes at room temperature. Excess stain was washed out
in 60% isopropyl alcohol, followed by washes in 30%
isopropyl alcohol and distilled water. Slides were coun-
terstained with hematoxylin and then rinsed with two
changes of tap water; coverslips were mounted with
glycerol. Slides were subsequently stored at 4C. Images
were captured on a BX60 microscope equipped with
a Microﬁre camera (both from Olympus America, Center
Valley, PA), using PictureFrame software version 2.1
(Optronics, Goleta, CA), and were analyzed with Adobe
Photoshop CS4 software.1402Treatment Studies
Tissue from an existing xenograft was dissociated using
a 100-mm mesh cell strainer into DPBS. Viable cells were
counted with Trypan Blue exclusion, centrifuged, and
resuspended in equal portions of DPBS and Matrigel (BD
Biosciences, San Jose, CA), and 5  105 cells were injected
subcutaneously. Tumors were measured with calipers.
When tumors reached approximately 5 mm in diameter,
mice were randomly assigned into placebo (vehicle) or
treatment groups, with a minimum of ﬁve mice per group.
Tumor volume was measured twice weekly and calculated
as tumor volume V Z 0.52 a2b, where a is the shorter and
b is the longer diameter.
Rapamycin powder (LC Laboratories, Woburn, MA) was
reconstituted in 100% ethanol to a stock solution of 10 mg/
mL and was stored at 20C. Fresh working solution was
made each time by diluting the stock solution to 1 mg/mL
with vehicle (5.68% Tween-80, 5.68% polyethylene glycol
400 in water). Rapamycin (4 mg/kg) in vehicle or an equal
volume of vehicle alone was administered via intraperito-
neal injection daily. Sorafenib pills were weighed, then
crushed into powder and stored at 20C. Powder was
dissolved into freshly made vehicle (12.5% ethanol, 12.5%
cremophor in water) to 20 mg/mL. Sorafenib (70 mg/kg) in
vehicle or an equal volume of vehicle alone was adminis-
tered via oral gavage daily. Mice were treated daily with one
of the following combinations: rapamycin vehicle and sor-
afenib vehicle, rapamycin drug and sorafenib vehicle, sor-
afenib drug and rapamycin vehicle, or rapamycin drug and
sorafenib drug. Body weight and tumor measurements were
collected every 3 to 4 days. Tumors were collected, and the
mouse was sacriﬁced if the tumor reached 1.5 cm in
diameter, or if the mouse lost >10% of its body weight
within 1 week, whichever occurred ﬁrst.
Triglyceride Quantiﬁcation
Triglycerides were quantiﬁed using a triglyceride colori-
metric assay kit according to the manufacturer’s protocol
(Cayman Chemical, Ann Arbor, MI). Brieﬂy, frozen tumor
samples from the treatment study were weighed and
homogenized in the manufacturer’s 1 standard diluent
assay reagent. After applying the manufacturer’s triglyc-
eride enzyme mixture, the triglyceride standard curve and
samples were read at 530 nm using a Benchmark Plus plate
reader (Bio-Rad Laboratories, Hercules, CA). Triglyceride
levels for each sample were normalized to the weight of
tissue homogenized.
RNA Isolation and Gene Expression Microarray
Patient tumor samples and xenograft passages were prepared
and RNA was isolated as described previously.9 For the
xenograft treatment studies, frozen tissue from LPSX1 and
LPSX3 vehicle-only and combination treatment groups wasajp.amjpathol.org - The American Journal of Pathology
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extracted with a MagNa Pure Compact nucleic isolation
system (both from Roche Diagnostics, Indianapolis, IN). A
low-input QuickAmp one-color labeling kit (Agilent Tech-
nologies, Santa Clara, CA) was used for ﬁrst-strand, second-
strand, and in vitro transcription reactions. Samples were
analyzed on Agilent SurePrint Human GE 8x60kmicroarrays
and scanned on an Agilent DNA microarray scanner (both
from Agilent Technologies) at the UCLA Clinical Micro-
array Core.
CGH and Gene Expression Analysis
DNA isolation and comparative genomic hybridization
(CGH) procedures for patient samples have been described
in detail previously.9 CGH Analytics software version 4.0
(Agilent Technologies) was used for copy number analysis,
using the ADM2 algorithm (threshold 5) with fuzzy zero
and centralization corrections to minimize background
noise. A minimum of three consecutive probes was required
to deﬁne a region as ampliﬁed or deleted.
In gene expression analysis, a two-tailed t-test was used
for comparing expression between groups. For a gene rep-
resented by multiple probes, its representative P value was
the lowest P value among the probes. Gene ontology anal-
ysis was performed using pathway databases downloaded
from Gene Ontology (http://www.geneontology.org/GO.
downloads.shtml) and the Broad Institute Molecular
Signature Database (http://www.broadinstitute.org/gsea/Figure 1 Xenograft strategy and correlation of DSS with tumor xenograftabil
tumors were portioned for histopathological, gene expression, and in vitro and in
had signiﬁcantly shortened median survival, compared with patients whose tumo
whose tumors did not engraft at all (n Z 15; P < 0.0001, ManteleCox test).
pathological features of the patient tumors are maintained in xenografts over ser
H&E stain) and serial passages of the resulting xenografts. Scale bar Z 100 mm
The American Journal of Pathology - ajp.amjpathol.orgmsigdb/index.jsp).10,11 Fisher’s exact test was used to
identify the gene ontology or biological pathway signiﬁ-
cantly enriched by differentially expressed genes between
groups (P < 0.05, two-tailed t-test, and fold change >1.5).
Cluster 3.0 software (http://bonsai.hgc.jp/wmdehoon/
software/cluster), based on the original algorithm of Eisen
et al,12 was used in hierarchical clustering analysis, in which
the expression proﬁle of each gene was ﬁrst transformed to
z-scores and then samples were clustered by using average
linkage method based on uncentered correlation coefﬁcients
as the distance metric among samples.
The Rank-Rank Hypergeometric Overlap algorithm (http://
systems.crump.ucla.edu/rankrank)13 was used to compare
gene expression data from our samples versus gene expression
of preadipocytes collected after 0 and 3 days of induction in
differentiation medium (the series of Söhle et al14; http://www.
ncbi.nlm.nih.gov/geo; GEO accession no. GSE28628).
Statistical Analysis
Ordinal logistic regression was performed on clinical data
from all 22 patients using STATA/SE version 12.1 software
(StataCorp, College Station, TX). Multiple predictors for
engraftment and passage capability were tested, including
patient age at diagnosis, sex, location of tumor, sample
origin (primary, recurrent, or metastatic tumor), chemo-
therapy before tumor sample collection, radiation therapy
before tumor sample collection, grade, size of tumor, pres-
ence of multifocal disease, patient history of other cancerity. A: Schematic of study design. Surgically resected LPS and xenografted
vivo studies. B: Patients whose tumors could be serially passaged (n Z 3)
rs engrafted but could not be passaged (n Z 4; P Z 0.01) and with those
For surviving patients, tick marks indicate the latest follow-up. C: Histo-
ial passages. Shown is a representative passageable patient sample (LPSX3;
.
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Smith et altype, presence and/or development of metastasis, and
histological subtype. The odds ratio (OR), a measure of
effect size, was calculated for each signiﬁcant variable in the
univariate ordinal regression analysis, with appropriate
conﬁdence intervals (CI). Given the small sample size (nZ
22), a trending level of P < 0.1 was used to reveal possible
inﬂuential variables; in the ﬁnal model, a P < 0.05 was used
to determine statistical signiﬁcance. Other statistical anal-
yses (ManteleCox test, one-way analysis of variance, and
Friedman test) were performed using GraphPad Prism
version 5.04 software (GraphPad Software, San Diego, CA),
with P < 0.05 considered signiﬁcant.
Results
Ability to Engraft and Passage LPS Tumor Correlates
with Disease-Speciﬁc Survival
To generate clinically relevant LPS models for investigating
molecular etiology and evaluating response to targeted
therapies, we used a xenotransplantation approach by
subcutaneously implanting fresh, surgically resected LPS
samples into NOD/SCID or NOD/SCID/IL2g/ (NSG)
mice (Figure 1A). Over a 2-year period, we implanted 22
surgically resected tumors (myxoid/round cell, nZ 5; WD,Table 1 Clinical and Pathological Data for Study Samples
ID Histology Grade Origin of sample Site
Tumors that did not engraft
1 Myxoid Low Primary Thigh
2 Myxoid/RC Int. Primary Thigh
3 Myxoid/RC High Primary Thigh
4 WD Low Primary RP
5 Cellular WD Low Primary RP
6 WD Low Primary RP
7 WD Low Recurrent RP
8 Cellular WD Low Recurrent RP
9 Cellular WD Low Recurrent RP
10 WD Low Recurrent RP
11 DD* High Primary RP
12 DD* High Primary RP
13 DD* High Primary Abdomen
14 DD* High Recurrent RP
15 DD* High Recurrent RP
Tumors that engrafted only
16 Myxoid/RC High Primary Gluteal
17 Myxoid/RC High Metastatic Abdomen
18 DD High Recurrent RP
19 DD* High Metastatic Flank
Tumors that engrafted and could be passaged
LPSX1 DD High Recurrent Abdomen
LPSX2 DD* High Recurrent Thigh
LPSX3 DD* High Primaryy RP
*Dedifferentiated arising from a well-differentiated tumor. All DD areas were p
processing.
yThe patient presented with metastatic lesions, but the sample came from the
F, female; M, male; AC, adjuvant chemotherapy; AWD, alive with disease; DD, d
chemotherapy; NED, no evidence of disease; RC, round cell; RP, retroperitoneum;
1404nZ 7; and DD, nZ 10). These tumors varied in grade, site
of origin, size, and treatment history (Table 1). Of the 10
DD samples, 8 came from tumors that had both WD and DD
components, but all DD areas were pathologically diag-
nosed as high grade, and a sarcoma pathologist (S.M.D.)
selected DD areas for processing. Within 6 months of
implantation, seven patient tumors successfully grew in
mice (2/5 myxoid/round cell, 0/7 WD, and 5/10 DD),
resulting in a 32% engraftment rate (Table 1). All seven
engrafted LPS tumors were high grade, and three of these
xenografts, LPSX1, LPSX2, and LPSX3, could be serially
passaged in mice (14% of all tumors, 43% of engrafted
tumors) for 10 to 17 passages. In contrast, cells isolated
directly from patient tumors failed to be serially passaged
under the same in vitro culture conditions (data not shown).
To determine whether any clinicopathological factors
inﬂuenced the ability to establish a xenograft, we evaluated
multiple patient characteristics for each sample. Given the
small sample size (nZ 22), this was largely an exploratory
analysis to determine possible clinical predictors of
a tumor’s successful passage and/or engraftment. Univariate
analysis of 12 clinical variables revealed that the size of
tumor (PZ 0.084; ORZ 0.90; 95% CIZ 0.80e1.01) and
presence of multifocal disease (P Z 0.058; OR Z 15.35;
95% CI Z 0.91e257.27) correlated with the ability of anSize (cm) Treatment Sex Age Patient status
29 XRT M 39 NED
16 XRT M 28 NED
9 XRT M 47 NED
15 F 58 NED
41 XRT F 51 NED
32 AC M 61 AWD
15 M 72 NED
3 XRT M 49 NED
20 XRT M 54 AWD
22 XRT M 43 AWD
31 XRT F 57 NED
30 M 86 DOD
13 XRT M 66 AWD
20 XRT F 60 NED
5 XRT F 86 DOD
16 AC, XRT F 29 NED
22 AC M 66 AWD
5 AC, XRT F 58 NED
4 NC, XRT F 61 DOD
12 NC, XRT F 51 DOD
15 XRT M 90 DOD
27 NC M 75 DOD
athologically diagnosed as high grade, and only DD areas were selected for
primary tumor.
edifferentiated; DOD, died of disease; Int., intermediate; NC, neoadjuvant
WD, well-differentiated; XRT, radiation therapy.
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multivariate analysis, tumor size (P Z 0.052; OR Z 0.85,
CI Z 0.72e1.00) and presence of multifocal disease (P Z
0.026; ORZ 38.6, CIZ 1.53e969.13) remained signiﬁcant.
Given the small sample size, however, and high variability in
the data, these results should be interpreted with caution.
Next, we aimed to speciﬁcally evaluate the association of
engraftment and passageability with disease-speciﬁc
survival (DSS). As expected, the ability to engraft and be
passaged signiﬁcantly correlated with poor DSS on
univariate analysis (P < 0.0001, ManteleCox test). Patients
whose samples could be xenografted and serially passaged
died of disease within 200 days of tumor removal (n Z 3),
in sharp contrast to those patients whose tumors did not
grow (nZ 15; P < 0.0001, ManteleCox test) (Figure 1B).
Patients whose samples engrafted but could not be passaged
also (n Z 4) had a signiﬁcantly better survival than those
whose samples could be passaged (n Z 3; P Z 0.01,
ManteleCox test) (Figure 1B). Such a correlation is
consistent with grade-associated DSS studies from our
research group on 46 independent LPS patients and anotherFigure 2 Gene expression analysis reveals unique features of xenograftabl
transcripts separates the xenograftable patient tumors and their xenografts from
amplicons (12q13.3wq23.1) reveals a set of genes speciﬁcally associated with t
The American Journal of Pathology - ajp.amjpathol.orggroup's study of 61 patients showing that patients with high-
grade LPS had signiﬁcantly shortened survival, compared
with patients with low grade LPS tumors.15,16 Taken
together, these data suggest that the xenograftability of LPS
can be used for studying key molecular and genetic alter-
ations associated with the aggressive phenotype of LPS.
Xenografted Tumors Recapitulate Histopathological
and Gene Expression Features of the Patient Tumors
To conﬁrm that the xenografts recapitulate the patient
disease, we compared surgically resected patient tumors
with their derivatives (ie, xenograft tumors that had been
passaged in vivo). Representative histological images from
the patient tumor LPSX3 and its resulting xenografts
passaged in vivo for 1 to 9 passages demonstrated that no
major morphological changes occurred during serial passage
(Figure 1C). We also compared in vitro cultured cells and
different tissue dissociation and maintenance methods
before transplantation into mice and found no resulting
histopathological differences or proliferation rates, ase tumors. A: Unsupervised hierarchical cluster analysis based on 41,000
other LPS samples. B: Further analysis of transcripts of chromosome 12q
he xenograftable patient tumors and their xenografts (yellow box).
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Figure 3 PTEN gene and protein expression in xenograftable tumors. A:
Gene expression of PTEN is lower in DD LPS, compared with benign lipomas,
but patient tumors and their derived xenograft tumors show even lower gene
expression. Mean expression of benign samples is indicated by a dotted line.
B: DSS is signiﬁcantly shortened in patients with low PTEN expression (PZ
0.0148, ManteleCox test). The cutoff for low versus high expression was
below the 95% CI from the mean expression of benign samples (shown in A).
C: Immunohistochemical analysis of PTEN shows high positive staining in
a benign lipoma, as well as of stromal cells (arrows) in LPSX3 patient tumor
and derived xenograft. Scale barZ 100 mm.
Smith et almeasured by Ki-67 index (Supplemental Figure S1). These
analyses demonstrated that in vivo passaged and culture-
derived xenografts maintained the histological features of
the patient tumors.
We also looked at speciﬁc genetic alterations associated
with LPS, to conﬁrm that the xenograft model accurately
reﬂects the patient disease. Previous work by our research
group9 and others17e21 identiﬁed characteristic amplicons
on chromosome 12q in most WD and DD LPS tumors. Our
CGH array analysis showed that passageable patient tumors
indeed carry ampliﬁcations in this region (Supplemental
Figure S2A). Amplicon-associated genes (eg, MDM2 and
CDK4) showed similar up-regulation in both the patient
tumors and their corresponding xenografts (Supplemental
Figure S2B). These analyses indicated that the xenograft
models recapitulate both histopathological and molecular
features of the patient disease and therefore are suitable
models for studying LPS.
Xenograftability Is Associated with Aggressive
Proliferation and Invasion Signatures and with Up-
Regulated PI3K/AKT/mTOR Pathway
To understand the mechanisms underlying xenograftability
and the associated decrease in DSS, we performed genome-
wide gene expression analysis. Our unsupervised cluster
analysis showed that the patient tumors cluster alongside
their xenografts and xenograft-derived cultured cells
(Figure 2A). The analysis also showed that gene expression
of patient tumors and their xenograft derivatives was closely
associated with that of other high-grade patient LPS tumors
in our database, suggesting that mining the unique gene
expression signature within this cluster may help identify
the molecular mechanisms underlying the aggressive
behavior of this subset of LPS. An example is our analysis
of chromosome segment 12q13.3wq23.1 (Figure 2B),
which includes the commonly detected MDM2eCDK4
amplicon (Supplemental Figure S2A). We found that the
patient tumors, xenografts, and xenograft-derived cultured
cells maintain their own cluster and carry a unique gene
expression signature (Figure 2B). Further global supervised
transcriptome analyses identiﬁed approximately 1000 genes
whose expressions are differentially altered between the
passaged tumors (nZ 3) and tumors that could be engrafted
but not passaged (nZ 3; tumor 16 was not included in gene
expression analysis) (P < 0.05, two-tailed t-test, fold change
>1.5). Importantly, several cell proliferation and invasion-
related pathways were signiﬁcantly up-regulated in the
passaged xenograft samples (Supplemental Table S1).
We focused on the alteration of the mTOR pathway,
because we hypothesized that PTEN, a tumor suppressor
upstream of mTOR, is responsible for the dys-regulated
mTOR pathway. AlthoughCGH analysis of the patient tumors
from which the xenografts were derived showed no genetic
alterations at the PTEN locus,9 expression analysis showed
signiﬁcantly decreased PTEN levels in DD LPS (n Z 16),1406compared with benign lipoma samples (nZ 10) (P < 0.001,
one-way analysis of variance) (Figure 3A). The patient
samples and their xenografts also showed low PTEN protein
levels, except that stroma and blood vessels had higher PTEN
intensity (Figure 3C; Supplemental Figure S3A). Furthermore,
patient tumors and their derived xenografts had the lowest
PTEN expression levels of all DD LPS (Figure 3, A and C),
supporting the notion that decreased PTEN expression, most
likely due to epigenetic mechanisms, may up-regulate the
PI3K/AKT/mTOR pathway. Using the expression levels of
the benign tumors as a baseline (below the 95% CI from the
mean expression of benign samples; Figure 3A), we stratiﬁed
the DD LPS into two groups based on PTEN expression levels
(Figure S3B). Importantly, low PTEN expression was corre-
lated with poor DSS (nZ 19; PZ 0.0148, ManteleCox test)
(Figure 3B), which suggests that the PTEN-controlled PI3K/
AKT/mTOR pathway is a potential prognostic signature and
therapeutic target for DD LPS.
LPS Xenografts with Low PTEN Expression Are Sensitive
to anti-mTOR and Multikinase Inhibitor Treatment
To test whether DD LPS with down-regulated PTEN expres-
sion and up-regulated mTOR pathway activity is sensitive to
targeted inhibition of the PI3K/AKT/mTOR pathway, we
treated our xenograft models with rapamycin, a speciﬁc
inhibitor of mTOR. Although rapamycin has been used clin-
ically for soft tissue sarcoma, it has not been formally evalu-
ated in LPS patients. Recent reports indicate that inhibition of
mTOR kinase or the PI3K/AKT pathwaymay cause feedback-
dependent activation of upstream AKT and receptor tyrosineajp.amjpathol.org - The American Journal of Pathology
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therefore included the multitargeted tyrosine kinase inhibitor
sorafenib in our study design. Sorafenib as a single agent
has been used in phase 2 trials for advanced soft tissue
sarcomas, including LPS, but failed to show signiﬁcant
clinical efﬁcacy.25 We reasoned that combining sorafenib
with rapamycin might block the rapamycin-induced feed-
back activation of upstream kinases and thus lead to
sustainable therapeutic effect.
The three passageable LPS xenografts (LPSX1, LPSX2,
and LPSX3) were treated daily with no drug (vehicle),
rapamycin only, sorafenib only, or a combination of rapa-
mycin and sorafenib. Tumor growth was monitored over the
course of 3 to 7 weeks, or until tumors reached 1.5 cm in
diameter. LPSX1 treated with rapamycin or combination
therapy showed signiﬁcantly reduced tumor growth, as
measured by tumor volume, compared with either theFigure 4 Tumor response to single and combination treatments. A: Tumor gr
combination treatment, but LPSX2 and LPSX3 did not show slowed tumor growth in
of treatment response, including necrosis and morphological changes suggestive
row) and high magniﬁcation (middle and bottom rows) show differentiation and
power images of differentiation (black boxes) and necrosis (red boxes). Data are
mm (low-power images); 50 mm (high-power images).
The American Journal of Pathology - ajp.amjpathol.orgvehicle-only or sorafenib-treated groups; however, LPSX2
and LPSX3 showed no reduction in tumor size, regardless
of treatment (Figure 4A; Supplemental Figure S4).
There are signiﬁcant limitations to the current standard
size-based RECIST criteria for monitoring response to
therapy in soft tissue sarcomas,26 because tumors may
undergo necrosis or differentiation without signiﬁcant
changes in tumor size. We therefore resected all xenograft
tumors and examined the effects of various treatments at the
histopathological level. In contrast to the size measurements,
all three xenograft models responded to rapamycin and to
combination treatment with signiﬁcant necrosis and reduced
cellularity, which was clearly identiﬁed in H&E-stained
sections (Figure 4B; Supplemental Figure S5). Although the
vehicle-only and sorafenib-treated tumors retained high
cellular density, rapamycin-treated tumors were more
differentiated with lower cellular density. In support of ourowth curves. LPSX1 showed slowed growth when treated with rapamycin or
response to any of the treatments. B: Histological analysis shows evidence
of differentiation. Representative images of LPSX3 (H&E stain) at low (top
necrotic areas. Boxed areas correspond (although not to scale) to the high-
expressed as means  SEM. nZ 3 or 4 per treatment group. Scale bars: 2.5
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Figure 5 Response of intracellular targets to single and combination treatment. Representative images from consecutive sections of LPSX3 show down-
regulation of p-S6 and relatively stable p-ERK levels from immunohistochemical staining in response to rapamycin, sorafenib, and combination treatment or
vehicle alone. Scale bar Z 50 mm.
Table 2 Quantiﬁcation of Immunohistochemical Analysis in LPS
Xenografts
Marker and
xenograft
Staining score (density/intensity)*
Vehicle Rapamycin Sorafenib Combination
p-S6
LPSX1 2/3þ 1/1þ 2/2þ 1/1þ
LPSX2 2/3þ 1/1þ 2/2þ 1/1þ
LPSX3 2/3þ 1/1þ 2/2þ 1/1þ
p-ERK
LPSX1 2/2þ 3/2þ 3/2þ 3/2þ
LPSX2 1/1þ 1/1þ 2/3þ 2/1þ
LPSX3 2/1þ 2/1þ 2/2þ 2/1þ
*Staining density is scored as <1, negative staining; 1, 1% to 25% of
tumor cells staining; 2, 26% to 74% of tumor cells staining; 3, 75% of
tumor cells staining. Staining intensity is scored as 1þ, weak; 2þ,
moderate; 3þ, strong.
Smith et alhypothesis, combination treatment enhanced the effects of
rapamycin, with more necrotic areas and further reduced
cellularity (Figure 4B; Supplemental Figure S5). In addition
to evaluating histopathological changes, we assessed the
intended pathway targets of the drugs using immunohisto-
chemistry. p-S6 was chosen as a surrogate marker of mTOR
activity, and p-ERK was chosen as a downstream surrogate
marker of sorafenib treatment. As expected, the levels of p-
S6 decreased in response to rapamycin or combination
treatment. p-ERK levels were relatively equal across treat-
ment groups, with positive staining present in both the
nucleus and the cytoplasm (Figure 5; Table 2). Although
ERK is known to translocate to the nucleus when phos-
phorylated, this activated form of the protein has been
observed in the cytoplasm in human melanoma cancer
samples.27 These histopathological changes suggest that,
even though tumor size did not differ among treatment
groups of LPSX2 and LPSX3, the tumors responded to
rapamycin or combination treatments similarly to LPSX1.
Xenograftable DD LPS Are More Progenitor-Like, and
Combination Treatment Induces Differentiation
Resulting in Decreased Progenitor Expression
Signature and Increased Lipid Content
Accumulated evidence suggests that different subtypes of
LPS may represent developmental blockages of adipocyte1408differentiation from mesenchymal stem cells.2 Inducing
differentiation could therefore be a potential therapeutic
strategy for LPS.28,29 One of the morphological changes we
observed after rapamycin or combination treatment was the
presence of cells that more closely resembled adipocytes,
suggesting potential differentiation. We therefore ﬁrst wan-
ted to determine whether the patient tumors that generated
serially passaged xenografts are more progenitor-like and,
second, whether the combination treatment can alleviate the
differentiation blockage.ajp.amjpathol.org - The American Journal of Pathology
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samples, we ﬁrst used the rankerank hypergeometric
overlap algorithm to compare the overlap of differentially
expressed genes in passaged versus nonpassaged patient
tumors with the differentially expressed genes of pre-
adipocytes and differentiated adipocytes (0 days versus 3
days after differentiation; the series of Söhle et al14). The
heat map generated from these comparisons (Figure 6A,
LPS) showed greatest similarity in the gene expressionThe American Journal of Pathology - ajp.amjpathol.orgproﬁle between the passaged tumors and undifferentiated
preadipocytes, whereas the nonpassaged tumors showed the
greatest similarity to preadipocytes at day 3 after differen-
tiation. We then performed the same analysis, comparing
the gene expression of vehicle-treated and combination-
treated samples with that of preadipocytes at 0 and 3 days
after differentiation (the series of Söhle et al),14 and found
that the combination treatment induced these DD LPS
samples to initiate the differentiation process (Figure 6A,
LPSX).
To further conﬁrm the differentiation phenotype, we
analyzed the fat content of the tumors. We ﬁrst looked for
the presence of lipid droplets by staining with Oil Red O
(Figure 6B). Rapamycin signiﬁcantly increased both the
number and the size of lipid droplets, especially near
necrotic areas; combination-treated tumors had a similar
extent of Oil Red Oepositive cells (data not shown), but
with massive necrosis (Figure 6B). Oil Red O staining also
showed signiﬁcant regional variations (data not shown). To
provide more quantitative measurement, we extracted
triglycerides from vehicle- and drug-treated tumor samples.
Although the response to the individual drugs varied, there
was a consistent increase in triglyceride levels in tumors
treated with combination therapy (Figure 6C). These results
suggest that the passaged tumors are less differentiated and
more stem-like or progenitor-like, at least in part because of
up-regulated PI3K pathway. Rapamycin and sorafenib
combination treatment not only caused massive tumor
necrosis, but also led to adipogenic differentiation of DD
LPS tumors that have reduced PTEN levels or hyperactive
PI3K/AKT/mTOR pathway.
Discussion
The xenograft system demonstrated in the present study
successfully recapitulates the human disease and creates
a ﬂexible and useful model for studying the molecular
mechanisms underlying LPS. This model also provides
a foundation on which new targets can be developed and
novel therapeutics tested.Figure 6 Combination treatment induces dedifferentiated liposarcoma
(DD LPS) differentiation. A: Heat maps compare the gene expression
signatures of patient tumors that were passaged (P) versus nonpassaged
(NP) (left) or vehicle (V) versus combination (C) treated tumors (right) to
the signature of preadipocytes at day 0 versus day 3 after differentiation.
The color indicates the log10 value of the hypergeometric enrichment
P value between the two signature gene sets. The high-heat areas show
high correlation between the genes up-regulated at day 0 (undifferenti-
ated) preadipocytes and the passaged (P) and vehicle (V) treated tumors,
whereas the nonpassaged (NP) and combination (C) tumors are most
similar to preadipocytes at day 3, after differentiation. B: Oil Red O staining
of LPSX3 reveals changes in lipid droplet size and intensity in response to
treatments. C: Triglyceride quantiﬁcation indicates increased lipid content
in all three xenografts when treated with combination therapy. Data are
expressed as means  SEM. n Z 4 to 8 per treatment group. *P < 0.05;
**P < 0.01; and ***P < 0.001, one-way analysis of variance. Original
magniﬁcation, 400. TG, triglycerides.
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Smith et alThis xenograft model system has the potential for prog-
nostic and therapeutic value. To conﬁrm such potential,
however, a larger number of samples would need to be
tested. Of the clinical variables we tested (including age,
sex, location of the tumor, and history of prior treatment;
Table 1), only size of tumor and presence of multifocal
disease correlated with graftability. Moreover, the capability
of the tumor to engraft and survive serial passaging corre-
lated directly with poor DSS, which is similar to results
from a recent study using a renal cell carcinoma xenograft
model.30 Thus, the ability of a tumor sample to engraft may
help identify those patients who will beneﬁt from more
aggressive treatment regimens. Additionally, because the
median interval to disease recurrence is approximately 16
months for patients with high-grade LPS,31 xenografts
generated from patient biopsies or resected tumors at the
time of initial presentation can be molecularly proﬁled and
interrogated with targeted therapies. This would allow
physicians to deﬁne appropriate treatment paradigms and to
institute personalized therapies that could be used to prevent
or treat disease recurrence.
Our gene expression analysis identiﬁed alterations
unique to the patient tumors that could be xenografted and
serially passaged, which suggests that these tumors are
more progenitor-like than the nonpassageable xenografts.
One of the malignant signatures identiﬁed through the
present study is up-regulated mTOR pathway activation and
lower PTEN gene and protein expression, which suggests
that these tumors may have increased sensitivity to the
mTOR inhibitor rapamycin. Because rapamycin treatment
alone often results in therapeutic resistance, we also
included the multikinase inhibitor sorafenib. Histological
evaluation of the tumors revealed a noticeable response in
all three passageable xenografts to the combination therapy,
with increased necrosis, decreased cell density, and changes
in cell morphology. Further analysis of lipid content and
gene expression revealed that the tumors treated with
a combination of rapamycin and sorafenib became more
differentiated.
Xenograft models of renal cell carcinoma generated from
patient samples have been shown to reﬂect clinical response
to targeted therapy,30 demonstrating the utility of these
models for preclinical evaluation of new therapies. The data
presented here show that a combination of rapamycin and
sorafenib has potential as a differentiation therapy for
PTEN-low or PI3K/AKT/mTOR pathwayeactivated DD
LPS. New mTOR inhibitors that have a greater ability to
inhibit mTORC1 activity,32 or dual inhibitors of mTOR and
PI3K that are able to prevent the AKT feedback loop,33 may
further improve the efﬁcacy of such combination therapies.
Another option is to include PPARg ligands as part of
treatment. A study using a myxoid LPS mouse model
demonstrated that addition of PPARg agonists enhanced
the tumor differentiation achieved by trabectedin treat-
ment.29 In the present study, we have identiﬁed a malignant
signature for stratiﬁcation of patients who may be responsive1410to differentiation therapy, which offers a promising avenue to
explore for future targeted and differentiation therapy of DD
LPS.
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